# India Asthma COPD Drugs Market

> India Asthma COPD Drugs Market Research Report By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension) and By Patient Group (Adult, Pediatric, Geriatric) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.88%
- **2024:** $ 2,500 Million
- **2025:** $ 2,597 Million
- **2035:** $ 3,800 Million
- **Key Players:** GlaxoSmithKline (GB), Boehringer Ingelheim (DE), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Merck & Co. (US), Sanofi (FR), Roche (CH), Mylan (US)

**Report ID:** MRFR/Pharma/47724-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-asthma-copd-drugs-market-49475

---

## Market Summary

## **India Asthma COPD Drugs Market Overview**

As per MRFR analysis, the India Asthma COPD Drugs Market Size was estimated at 2.14 (USD Billion) in 2023.The India Asthma COPD Drugs Market Industry is expected to grow from 2.5(USD Billion) in 2024 to 4 (USD Billion) by 2035. The India Asthma COPD Drugs Market CAGR (growth rate) is expected to be around 4.365% during the forecast period (2025 - 2035).

**Key India Asthma COPD Drugs Market Trends Highlighted**

In India, the asthma and COPD market is growing rapidly and faces opportunities because of key drivers. The most important one is the increasing cases of chronic respiratory disorders due to urbanization, pollution, and lifestyle choices like smoking. The Indian government has also been working on healthcare access initiatives and programs for overcoming asthma and COPD, which is also helping fuel expansion. There is an increased focus on respiratory health among patients and practitioners which is also creating demand for new treatment options.

There are great opportunities in India asthma and COPD drugs market due to advances in technology and biotechnology.

The introduction of new therapies such as biologics and biosimilars creates opportunities for pharmaceutical companies to expand their brands into segments of the population that are looking for advanced treatment options. In addition, the growing e-pharmacy industry has improved access to essential drugs for patients so they can follow their treatment programs better. There have been recent shifts to personalized medicine which focuses on specific treatment methodologies based on unique therapy reactions from each patient. There is a broader preventive approach for dealing with asthma and COPD such as vaccinations for respiratory infections that is emerging.

Policies to improve the quality of air and increase physical activity have practically dampened the existence of respiratory ailments. At a macro level, the India asthma and COPD drugs market is developing actively, which captures the efforts of practitioners to address the health status of the population.

**India Asthma COPD Drugs Market Drivers**

**Increasing Prevalence of Respiratory Diseases**

In India, respiratory diseases, including asthma and Chronic Obstructive Pulmonary Disease (COPD), are becoming increasingly prevalent due to factors such as urbanization, air pollution, and lifestyle changes. The Ministry of Health and Family Welfare in India has reported that approximately 10% of the Indian population suffers from asthma, and nearly 15-20% of adults are affected by COPD. 

Moreover, according to a study published in the Lancet, India is expected to witness a rise in respiratory ailments due to a growing elderly population and increased exposure to environmental pollutants.This alarming trend drives the demand for effective drugs in the India Asthma COPD Drugs Market Industry. 

With the rising healthcare expenditures in India, which is projected to reach 2.5% of the Gross Domestic Product (GDP) by 2025, the market for asthma and COPD drugs is anticipated to grow significantly to cater to the needs of millions suffering from these conditions.

**Government Initiatives and Support**

The Indian government has launched various initiatives aimed at improving healthcare infrastructure and access to treatment for respiratory diseases. The National Health Mission and the Ayushman Bharat scheme are two government initiatives providing better healthcare access to underprivileged populations. According to government reports, these initiatives have resulted in a 30% increase in hospital visits for asthma and COPD related treatments over the last five years.Such governmental support is likely to facilitate easier access to asthma and COPD drugs, thereby boosting the growth of the India Asthma COPD Drugs Market Industry.

**Innovations in Drug Development**

The India Asthma COPD Drugs Market Industry is witnessing significant advancements in drug formulations and delivery mechanisms, driven by increased Research and Development investments by pharmaceutical companies. For instance, organizations like Cipla and Sun Pharmaceutical Industries are focusing on developing combination inhalers and biologics that improve patient outcomes. Research indicates that innovative drug delivery systems can enhance medication adherence by as much as 40%.As more companies invest in innovative technologies, the overall market for asthma and COPD medications in India is expected to experience substantial growth.

**Rise in Healthcare Awareness and Education**

There is a growing awareness regarding respiratory diseases in India, spurred by educational campaigns and outreach programs conducted by various health organizations. The Indian Council of Medical Research (ICMR) has noted a 25% increase in awareness about asthma and COPD in the last few years due to focused public health campaigns. As individuals become more informed about the symptoms, treatment options, and management strategies for these diseases, the demand for asthma and COPD medications is likely to grow.This rise in healthcare awareness directly contributes to the expansion of the India Asthma COPD Drugs Market Industry.

**India Asthma COPD Drugs Market Segment Insights**

**Asthma COPD Drugs Market Drug Class Insights**

The India Asthma COPD Drugs Market exhibits a significant segmentation within the Drug Class category, showcasing various therapeutic options tailored to address respiratory ailments such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Among these, Bronchodilators play a crucial role in relieving airway constriction and enhancing airflow, which is vital for patients experiencing wheezing and shortness of breath. 

These medications are essential in both emergency situations and routine management of chronic respiratory conditions, contributing to the overall improvement of lung function in affected individuals.Corticosteroids are another key component, widely recognized for their anti-inflammatory properties; they effectively reduce inflammation in the airways, significantly improving patient outcomes in the long term. The prominence of Combination Drugs reflects an important trend in treatment strategies, as these formulations combining bronchodilators and corticosteroids not only simplify therapy regimens for patients but also ensure optimized therapeutic efficacy.

Leukotriene Modifiers, while perhaps less dominant in market share compared to the aforementioned classes, are nonetheless crucial in managing asthma by controlling bronchial hyperresponsiveness, thus aiding those with allergic asthma and providing a unique mechanism of action that complements other treatments.

This diversified Drug Class segmentation allows for a comprehensive approach in addressing the unique needs of patients across India, particularly given the country's high prevalence of asthma and COPD, fueled by factors such as urban pollution and smoking. Therefore, understanding the role and significance of each drug class is essential for stakeholders aiming to improve patient care within the rapidly evolving landscape of respiratory health management in India.

**Asthma COPD Drugs Market Route of Administration Insights**

In the India Asthma COPD Drugs Market, the Route of Administration plays a pivotal role in determining treatment efficiency and patient adherence. The market is characterized by diverse administration methods, including inhalation, oral, injection, and nasal routes, each serving distinct patient needs and therapeutic objectives. Inhalation methods dominate this space, offering rapid drug delivery directly to the lungs, making it particularly effective for asthma and COPD management.

This route is significantly favored for its ability to minimize systemic side effects while maximizing local treatment efficacy.Oral administration is also prevalent due to its convenience and ease of use, appealing to a broad demographic and enhancing patient compliance. 

Injection methods, though less common, are important for delivering biologics and long-acting agents that require precise dosing and sustained action. Lastly, the nasal route offers an alternative for patients who may have difficulties with inhalers, providing a quick onset of action. As healthcare initiatives in India focus on enhancing accessibility to effective treatments for respiratory conditions, these routes of administration are integral to shaping the future landscape of the India Asthma COPD Drugs Market by meeting the diverse needs of patients.

**Asthma COPD Drugs Market Application Insights**

The India Asthma COPD Drugs Market focuses significantly on the Application segment, which encompasses areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, and Pulmonary Hypertension. The market surrounding asthma represents a crucial aspect, as it affects millions of individuals in India, with increasing urbanization and pollution contributing to its prevalence. COPD is also critical, being a major cause of morbidity and mortality in the country, emphasizing the need for effective treatment options. Allergic Rhinitis is on the rise due to changing environmental factors and lifestyles, underscoring the demand for intervention in the pharmaceutical landscape.

Furthermore, Pulmonary Hypertension, although less common, still requires considerable attention due to its impact on patients' quality of life. Growth drivers in this segment include heightened awareness, advanced drug formulations, and improved healthcare infrastructure in India. However, challenges such as high treatment costs and varying patient adherence levels persist. Overall, the Application segment plays an important role in the India Asthma COPD Drugs Market, underscoring the significance of targeted therapies to manage chronic respiratory conditions effectively.

**Asthma COPD Drugs Market Patient Group Insights**

The Patient Group segment within the India Asthma COPD Drugs Market illustrates a diverse demographic with unique healthcare needs driven by varying age groups. Adults typically represent a significant portion of the market due to the higher prevalence of chronic respiratory diseases linked to lifestyle factors and environmental pollution, particularly in urban areas.

Meanwhile, the pediatric group emerges as a crucial segment, as early intervention in childhood asthma can lead to better management of symptoms and overall long-term health outcomes.The geriatric population also plays a vital role given their increased susceptibility to respiratory ailments due to age-related decline in lung function and the presence of comorbidities. 

This population necessitates targeted therapies that consider their complex health profiles and medication sensitivities. With the growing awareness and increased healthcare access in India, particularly among these patient groups, the demand for effective asthma and COPD management solutions is anticipated to rise, revealing opportunities for pharmaceutical innovations.Thus, understanding the unique characteristics and requirements of each demographic within the Patient Group is essential to advance treatment strategies and improve health outcomes across India.

**India Asthma COPD Drugs Market Key Players and Competitive Insights**

The India Asthma COPD Drugs Market has been experiencing a significant transformation, marked by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). This market is driven by a combination of factors including rising pollution levels, changing lifestyles, and an increase in the geriatric population, resulting in a higher demand for effective medications and therapies. The competition in this sector is intense, with numerous domestic and international players striving to capture market share.

The emphasis on research and development, along with strategic partnerships and collaborations, has become crucial for companies looking to innovate and meet the evolving needs of healthcare professionals and patients alike. 

New product launches and a focus on cost-effective solutions are also prominent trends shaping the competitive landscape of the asthma and COPD market in India.Teva Pharmaceutical Industries holds a robust presence in the India Asthma COPD Drugs Market, recognized for its commitment to providing high-quality generic and specialty pharmaceuticals. Teva’s strengths lie in its extensive research and development capabilities, which enable the company to innovate and bring forth new treatments tailored for patients suffering from respiratory diseases. The company leverages its global expertise while focusing on regional needs, resulting in products that address specific demographic requirements. 

Teva also benefits from its established distribution networks in India, which allows for better accessibility of its medications to healthcare providers and patients. The company's leadership in generics and focus on patient-centric solutions have positioned it favorably within this competitive market.Zydus Cadila is a prominent player in the India Asthma COPD Drugs Market, known for its comprehensive portfolio of respiratory therapies that cater to a wide range of patient needs. The company has developed several key products specifically targeting asthma and COPD, contributing to its strong reputation in the sector. 

Zydus Cadila’s market presence is strengthened by its continuous investment in research and development, allowing it to introduce innovative solutions that align with global healthcare standards. The company has also engaged in strategic mergers and acquisitions to enhance its capabilities in the respiratory space, thereby expanding its footprint in the Indian market. Furthermore, Zydus Cadila's commitment to affordability and accessibility, combined with its efficient manufacturing processes, has made it a trustworthy choice for patients and healthcare providers alike, solidifying its position in the competitive landscape of asthma and COPD medications in India.

**Key Companies in the India Asthma COPD Drugs Market Include:**

- Teva Pharmaceutical Industries
- Zydus Cadila
- AstraZeneca
- Novartis
- Lupin
- GlaxoSmithKline
- Merck and Co.
- Boehringer Ingelheim
- Alkem Laboratories
- Sun Pharmaceutical Industries
- Dr. Reddy's Laboratories
- Cipla
- Sanofi
- Mylan
- RPG Life Sciences

**India Asthma COPD Drugs Market Industry Developments**

In the India Asthma and Chronic Obstructive Pulmonary Disease (COPD) drugs market, recent developments include heightened competition among major players such as Teva Pharmaceutical Industries, Zydus Cadila, AstraZeneca, and Novartis as they launch innovative therapies and inhalers targeting asthma management. Notably, in August 2023, Merck and Co. received regulatory approval for a new combination inhaler that significantly improves lung function for asthma patients, demonstrating the industry's focus on advancing treatment options. 

Additionally, Lupin and GlaxoSmithKline have entered partnerships to enhance their distribution networks in India, aiming to improve access to their asthma and COPD medications. Over the past couple of years, the market has experienced considerable growth, driven by rising air pollution levels and increased public awareness about respiratory diseases. 

This growth is evident as the cumulative market valuation is expected to reach approximately USD 1.5 billion by the end of 2023, indicating a strong demand for these medications. Furthermore, the introduction of biosimilars by companies like Cipla and Sanofi has altered competitive dynamics, allowing for more affordable treatment options in the asthma and COPD segment.

**India Asthma COPD Drugs Market Segmentation Insights**

- **Asthma COPD Drugs Market Drug Class Outlook** - Bronchodilators - Corticosteroids - Combination Drugs - Leukotriene Modifiers
- **Asthma COPD Drugs Market Route of Administration Outlook** - Inhalation - Oral - Injection - Nasal
- **Asthma COPD Drugs Market Application Outlook** - Asthma - Chronic Obstructive Pulmonary Disease - Allergic Rhinitis - Pulmonary Hypertension
- **Asthma COPD Drugs Market Patient Group Outlook** - Adult - Pediatric - Geriatric

## Market Drivers

### Rising Healthcare Expenditure

The increase in healthcare expenditure in India is a significant driver for the asthma copd-drugs market. With the government's commitment to improving healthcare infrastructure and access, spending on health services has risen substantially. Reports indicate that healthcare expenditure as a % of GDP has increased from 3.5% to approximately 4.5% in recent years. This trend suggests a growing recognition of the importance of addressing chronic diseases, including asthma and COPD. As more funds are allocated to respiratory health, the availability of asthma copd-drugs is likely to improve, facilitating better management of these conditions. Enhanced insurance coverage and reimbursement policies may further support this growth, making treatments more accessible to patients.

### Increased Awareness and Education

The growing awareness and education regarding respiratory diseases are pivotal in shaping the asthma copd-drugs market in India. Public health campaigns and educational initiatives by both governmental and non-governmental organizations have led to a better understanding of asthma and COPD among the population. This heightened awareness encourages individuals to seek medical advice and treatment, thereby increasing the demand for asthma copd-drugs. Additionally, healthcare professionals are being trained to recognize and manage these conditions more effectively, which may lead to earlier diagnosis and treatment. As awareness continues to rise, the market is expected to benefit from an influx of patients seeking appropriate therapies.

### Advancements in Pharmaceutical Research

Ongoing advancements in pharmaceutical research are significantly influencing the asthma copd-drugs market in India. The development of novel drug formulations and delivery systems, such as inhalers and nebulizers, enhances the efficacy of treatments for asthma and COPD. Research institutions and pharmaceutical companies are increasingly investing in clinical trials to explore new therapeutic agents, including biologics and small molecules. This investment is expected to yield innovative solutions that address unmet medical needs, potentially increasing market share. Furthermore, the introduction of generic drugs following patent expirations is likely to make treatments more accessible and affordable, thereby expanding the market reach and improving patient outcomes.

### Regulatory Support and Policy Framework

The regulatory environment in India is evolving to support the asthma copd-drugs market. The government has implemented policies aimed at streamlining drug approval processes and enhancing the quality of medications available in the market. Initiatives to promote research and development in respiratory therapies are also gaining traction, potentially leading to a more robust pipeline of innovative treatments. Furthermore, the establishment of guidelines for the management of asthma and COPD by health authorities is likely to standardize treatment protocols, encouraging the use of effective drugs. This supportive regulatory framework may foster a conducive environment for market growth, attracting investments and encouraging pharmaceutical companies to develop new products.

### Increasing Prevalence of Respiratory Diseases

The rising incidence of respiratory diseases, particularly asthma and COPD, is a crucial driver for the asthma copd-drugs market in India. According to recent health surveys, approximately 15-20% of the Indian population suffers from asthma, while COPD affects around 5-10% of adults. This growing patient base necessitates the development and availability of effective medications, thereby propelling market growth. The increasing urbanization and pollution levels in cities further exacerbate respiratory conditions, leading to a higher demand for asthma copd-drugs. As healthcare providers seek to address these challenges, the market is likely to expand, with a focus on innovative therapies and treatment options tailored to the needs of the Indian population.

## Future Outlook

The [Asthma COPD Drugs Market](https://www.marketresearchfuture.com/reports/asthma-copd-drugs-market-8749) is projected to grow at a 3.88% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in drug formulations.

**New opportunities:**

- Development of personalized inhalation therapies for enhanced patient compliance.
- Expansion of telehealth services for remote patient monitoring and medication management.
- Investment in AI-driven drug discovery to accelerate new product development.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Drug Class: Bronchodilators (Largest) vs. Combination Drugs (Fastest-Growing)

In the India asthma copd-drugs market, the distribution of market share among drug classes reveals that bronchodilators hold the largest share, reflecting their dominance in asthma and COPD management. This segment is followed closely by corticosteroids, while combination drugs and leukotriene modifiers also contribute to the market dynamics, albeit to a lesser extent. The popularity of bronchodilators can be attributed to their immediate efficacy in providing relief to patients experiencing respiratory distress.

Growth trends indicate that while bronchodilators remain essential, combination drugs are emerging as the fastest-growing segment due to their ability to offer multifaceted therapy options for asthma and COPD. The increasing prevalence of these respiratory conditions, coupled with a growing preference for combination therapies that enhance patient compliance and outcomes, drives this shift. Additionally, technological advancements in drug delivery systems are also supporting the growth of the combination drugs segment.

Bronchodilators: Largest vs. Combination Drugs: Fastest-Growing

Bronchodilators are recognized as the dominant drug class in the market, providing critical relief through their ability to widen air passages in the lungs. They are widely prescribed and have established a strong foothold due to their effectiveness. In contrast, combination drugs, which incorporate multiple therapeutic agents into a single formulation, are rapidly gaining traction as they offer synergistic effects that manage symptoms more efficiently. These drugs are seen as emerging contenders, appealing to patients and healthcare providers for their convenience and improved adherence. As the market evolves, the shift towards combination therapies highlights a growing need for innovative solutions in managing chronic respiratory diseases.

### By Route of Administration: Inhalation (Largest) vs. Oral (Fastest-Growing)

In the India asthma copd-drugs market, the segment of Inhalation shows a significant market share, being recognized as the largest route of administration. It is favored for its targeted delivery, allowing for effective management of asthma and COPD symptoms. On the other hand, Oral administration is increasingly gaining traction, capturing attention for its ease of use and the emerging trend of users preferring more convenient treatment options. Consequently, this segment is rapidly growing due to evolving patient preferences and technological advancements.

Growth trends indicate that the inhalation segment remains essential due to its effectiveness, while the oral segment is on the rise, driven by the increase in prevalent therapeutic needs. Innovations in formulation and delivery mechanisms are facilitating improvements in patient adherence and satisfaction. Furthermore, an aging population and rising pollution levels are contributing to a higher demand for asthma and COPD treatments, ultimately promoting the growth of both Inhalation and Oral routes in the market.

Inhalation: Dominant vs. Oral: Emerging

Inhalation as a route of administration dominates the market due to its rapid onset of action and direct targeting of the lungs, which is crucial for managing respiratory conditions like asthma and COPD. It encompasses various devices such as metered-dose inhalers and nebulizers, which are designed to deliver medication effectively. Conversely, Oral administration represents an emerging trend, becoming increasingly popular among patients who prioritize convenience and ease of use. This segment is characterized by innovative formulations that enhance bioavailability and patient compliance, making it a favorable option for long-term treatment regimens. The contrasting characteristics of these segments highlight the evolving landscape of the India asthma copd-drugs market.

### By Application: Asthma (Largest) vs. Chronic Obstructive Pulmonary Disease (Fastest-Growing)

In the India asthma copd-drugs market, the application segment is predominantly led by asthma, which commands a substantial share due to the high prevalence of this condition among the population. Chronic Obstructive Pulmonary Disease follows, showing significant traction as healthcare awareness increases and treatment options diversify. The market also sees contributions from allergic rhinitis and pulmonary hypertension, albeit at smaller scales, reflecting the varied respiratory issues present in the population.

The growth trends in this segment are driven by rising pollution levels, increasing smoking rates, and a growing elderly population susceptible to respiratory diseases. Innovative therapies and advancements in drug delivery systems are propelling the expansion of chronic obstructive pulmonary disease treatments. The overall demand for effective respiratory drugs fuels the market, with a strong focus on patient-centric solutions enhancing adherence to therapy.

Asthma: Dominant vs. Chronic Obstructive Pulmonary Disease: Emerging

Asthma remains the dominant application in the India asthma copd-drugs market, characterized by a vast array of treatment options ranging from inhalers to biologics. This segment benefits from established therapies and growing awareness among healthcare professionals about managing asthma effectively. On the other hand, Chronic Obstructive Pulmonary Disease is emerging rapidly due to increasing recognition of the condition's impact on patients' quality of life. The latter segment is witnessing advancements in pharmacological innovations aimed at improving lung function and reducing exacerbations. The healthcare system's shift toward preventive care and tailored treatment plans further fosters growth, positioning chronic obstructive pulmonary disease as a significant focus area in the respiratory drug market.

### By Patient Group: Adult (Largest) vs. Pediatric (Fastest-Growing)

In the India asthma copd-drugs market, the distribution of market share among the patient groups showcases that the Adult segment holds the largest share, driven by the higher prevalence of asthma and COPD among adults. This segment's strong demand is mainly attributed to lifestyle factors, pollution, and increased awareness about respiratory diseases, leading to a higher adoption of therapeutic solutions. On the other hand, the Pediatric segment is gaining traction as awareness improves regarding the early detection and treatment of respiratory conditions in children. Parents are increasingly seeking effective treatments for managing their children's asthma and COPD symptoms, thus propelling the segment's growth.

Growth trends indicate a robust development phase for the Pediatric segment, which is witnessing the fastest growth due to rising urbanization and changing lifestyle habits among young families. The increasing burden of respiratory diseases among children, combined with government initiatives promoting awareness and education, is expected to drive demand in this segment. Moreover, innovations in drug formulations specific to pediatric needs are likely to further accelerate market growth, making it a focal point for future investments in research and development.

Adult (Dominant) vs. Pediatric (Emerging)

The Adult segment remains the dominant force in the India asthma copd-drugs market, reflecting a broad base of patients and a comprehensive range of treatment options tailored to adult needs. This segment benefits from a well-established market presence, physician endorsements, and a variety of therapeutic drugs available. In comparison, the Pediatric segment, while currently emerging, is witnessing significant growth as awareness around children's respiratory health increases. The demand is driven by comprehensive treatment plans, innovative delivery mechanisms catering to children, and growing parental concerns about pediatric asthma and COPD. As research progresses, the Pediatric segment is expected to adopt more specialized drugs, potentially shaking up the market dynamics as it gains prominence.

## Competitive Benchmarking

The asthma copd-drugs market in India is characterized by a dynamic competitive landscape, driven by increasing prevalence of respiratory diseases and a growing demand for effective therapeutic solutions. Major players such as GlaxoSmithKline (GB), Boehringer Ingelheim (DE), and AstraZeneca (GB) are strategically positioned to leverage innovation and regional expansion. GlaxoSmithKline (GB) focuses on developing advanced inhalation therapies, while Boehringer Ingelheim (DE) emphasizes its commitment to research and development, particularly in biologics. AstraZeneca (GB) is enhancing its portfolio through strategic partnerships and acquisitions, which collectively shape a competitive environment that is increasingly focused on innovation and patient-centric solutions.Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of key players like Novartis (CH) and Merck & Co. (US) suggests a trend towards consolidation, as companies seek to strengthen their market positions through strategic collaborations and mergers.

In October  GlaxoSmithKline (GB) announced a partnership with a leading Indian biotechnology firm to co-develop a novel inhalation device aimed at improving drug delivery efficiency. This strategic move is likely to enhance GlaxoSmithKline's competitive edge by integrating local expertise and addressing specific patient needs in the Indian market. Such collaborations may also facilitate faster regulatory approvals and market entry.

In September  AstraZeneca (GB) launched a new digital health platform designed to support asthma and COPD patients in managing their conditions more effectively. This initiative underscores AstraZeneca's commitment to digital transformation and patient engagement, potentially leading to improved treatment adherence and outcomes. The integration of technology into healthcare solutions is becoming increasingly vital in the current market landscape.

In August  Boehringer Ingelheim (DE) expanded its manufacturing capabilities in India, focusing on the production of biologics for respiratory diseases. This expansion not only signifies Boehringer Ingelheim's long-term commitment to the Indian market but also reflects a broader trend of companies investing in local production to enhance supply chain reliability and reduce dependency on imports.

As of November  current competitive trends in the asthma copd-drugs market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development and patient management. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to deliver advanced, patient-centric solutions.

## Recent News & Developments

In the India Asthma and Chronic Obstructive Pulmonary Disease (COPD) drugs market, recent developments include heightened competition among major players such as Teva Pharmaceutical Industries, Zydus Cadila, AstraZeneca, and Novartis as they launch innovative therapies and inhalers targeting asthma management. Notably, in August 2023, Merck and Co. received regulatory approval for a new combination inhaler that significantly improves lung function for asthma patients, demonstrating the industry's focus on advancing treatment options. 

Additionally, Lupin and GlaxoSmithKline have entered partnerships to enhance their distribution networks in India, aiming to improve access to their asthma and COPD medications. Over the past couple of years, the market has experienced considerable growth, driven by rising air pollution levels and increased public awareness about respiratory diseases. 

This growth is evident as the cumulative market valuation is expected to reach approximately USD 1.5 billion by the end of 2023, indicating a strong demand for these medications. Furthermore, the introduction of biosimilars by companies like Cipla and Sanofi has altered competitive dynamics, allowing for more affordable treatment options in the asthma and COPD segment.

## Report Scope

| MARKET SIZE 2024 | 2500.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2597.0(USD Million) |
| MARKET SIZE 2035 | 3800.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.88% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | GlaxoSmithKline (GB), Boehringer Ingelheim (DE), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Merck & Co. (US), Sanofi (FR), Roche (CH), Mylan (US) |
| Segments Covered | Drug Class, Route of Administration, Application, Patient Group |
| Key Market Opportunities | Emerging biologics and personalized therapies are reshaping the asthma copd-drugs market landscape. |
| Key Market Dynamics | Rising demand for innovative asthma and COPD therapies drives competition and regulatory adaptations in the market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the asthma and COPD drugs market in India as of 2024?**
A: The overall market valuation was $2500.0 Million in 2024.

**Q: What is the projected market valuation for the asthma and COPD drugs market in India by 2035?**
A: The projected valuation for 2035 is $3800.0 Million.

**Q: What is the expected CAGR for the asthma and COPD drugs market in India during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 3.88%.

**Q: Which drug class had the highest valuation in the asthma and COPD drugs market in 2024?**
A: Bronchodilators had a valuation range of $800.0 Million to $1200.0 Million in 2024.

**Q: What are the key routes of administration for asthma and COPD drugs in India?**
A: The key routes of administration include Inhalation, Oral, Injection, and Nasal.

**Q: What was the valuation range for combination drugs in the asthma and COPD drugs market in 2024?**
A: Combination drugs had a valuation range of $700.0 Million to $1100.0 Million in 2024.

**Q: Which patient group is projected to have the highest market valuation in the asthma and COPD drugs market?**
A: The Adult patient group is projected to have a valuation range of $1500.0 Million to $2200.0 Million.

**Q: What is the valuation range for chronic obstructive pulmonary disease drugs in 2024?**
A: Chronic Obstructive Pulmonary Disease drugs had a valuation range of $900.0 Million to $1300.0 Million in 2024.

**Q: Who are the key players in the asthma and COPD drugs market in India?**
A: Key players include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and others.

**Q: What is the valuation range for leukotriene modifiers in the asthma and COPD drugs market in 2024?**
A: Leukotriene modifiers had a valuation range of $400.0 Million to $600.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-asthma-copd-drugs-market-49475*